Aged Care Royal Commission – Case study

CO
Carroll & O'Dea

Contributor

Established over 120 years ago, Carroll & O’Dea Lawyers offers expert advice and strong advocacy for clients. With a commitment to high-level service and legal expertise in all areas, they blend tradition with modern skills.
This case study concerned the physical and chemical restraint of a vulnerable man with Alzheimer's Disease and Dementia.
Australia Food, Drugs, Healthcare, Life Sciences

As the hearings for the Royal Commission into Aged Care continue, one particularly distressing case study emerged which concerned the physical and chemical restraint of a vulnerable man suffering from Alzheimer's Disease and Dementia.

The elderly patient was a resident at the Garden View Aged Care Facility in New South Wales. His family raised concerns for his safety and wellbeing when evidence revealed that the patient was being prescribed multiple dosages of the psychotropic medication, Risperidone, which is a medication used to treat aggression and irritability in illnesses such as Dementia. Of particular concern was the fact that the patient was being prescribed the medication by two different medical practitioners simultaneously, despite one of the doctors admitting that medications such as Risperidone are "last resort medications".

In addition to being chemically restrained, it was also revealed that the patient was being physically restrained for periods of up to 13-14 hours a day. This disturbing incident was explained as an oversight, due to the fact that the permission sheets for implementing physical restraints did not advise as to how long the restraints could be used against a patient.

This case study must be restricted to its circumstances, however, it reflects the fearless approach of the Commission in investigating instances where standards fall well below community expectations.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More